Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To investigate the efficacy of HMI-115 compared to placebo in treating Androgenic Alopecia patients for 24 weeks
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| placebo-Q2W | Placebo Comparator | placebo, 0mg/vials |
|
| HMI-115-120mg-Q4W | Active Comparator | HMI-115, 60mg/vials |
|
| HMI-115-240mg-Q4W | Active Comparator | HMI-115, 60mg/vials |
|
| HMI-115-240mg-Q2W | Active Comparator | HMI-115, 60mg/vials |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| placebo-Q2W | Drug | placebo, 0mg，SC，Q2W，12 cycles |
| |
| HMI-115-120mg-Q4W |
| Measure | Description | Time Frame |
|---|---|---|
| The Rate of Target Arean Hair Count (TAHC) | The mean change in TAHC of non-vellus from baseline | 24 Weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Hair Growth State Assessed by Hair Growth Questionnaire Assessment (HGQA) | To assess the hair growth by 7-question questionnaire and summary the number and percentage of subjects in each category for each HGQA question. | 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks |
| Target Area Hair Count (TAHC) change from baseline |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Subject with history of scalp radiation or surgery which could interfere study assessment (e.g., hair transplantation surgery).
Subject with history of scalp laser treatment within 6 months prior screening, including but not limited to, low level laser, and fractional laser, etc.
Subject with history of hair weaves within 3 months prior screening.
Subject has a current history of hyperthyroidism or uncontrolled hypothyroidism.
Subject has, in the Investigator's opinion, uncontrolled hypertension (systolic blood pressure [SBP] > 159 mmHg, diastolic blood pressure [DBP] > 99 mmHg).
Subject has any of the following conditions within 6 weeks prior to Screening:
Subject has high fever, major surgery, or ten percent or more weight decrease within three months before screening.
Subject with history of active malignancy (with or without systemic chemotherapy), except treated basal cell carcinoma of the skin (besides scalp).
Subject plans to schedule elective surgery during the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking University People's Hospital | Beijing | Beijing Municipality | 100035 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000505 | Alopecia |
| ID | Term |
|---|---|
| D007039 | Hypotrichosis |
| D006201 | Hair Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
HMI-115, 120mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle) |
|
| HMI-115-240mg-Q4W | Drug | HMI-115, 240mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle) |
|
| HMI-115, 240mg-Q2W | Drug | HMI-115, 240mg，SC，Q2W，12 cycles |
|
The mean change in TAHC of non-vellus from Baseline |
| 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks |
| Rate of Target Area Hair Width (TAHW) | The mean change in TAHW of non-vellus from baseline | 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks |
| Investigator Global Assessment (IGA) | Summary of subject number and percentage in each IGA category | 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks |
| Subject Self-Assessment (SSA) | Summary of subject number and percentage in each SSA category | 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks |
| Norwood-Hamilton Grade change from baseline | Summary of subject number and percentage in each grade of Norwood-Hamilton Scale | 12 weeks, 24 weeks, and 36 weeks |
| Frequencies and percentages of Adverse event (AE) | Frequency and percentages of subjects with treatment-emergent AE (TEAE) will be calculated and TEAE will be summarized by systematic organ classification (SOC), preferred term (PT), relationship to study treatment, maximum severity, whether resulting in death, whether resulting in study treatment discontinuation, belong to serious AE (SAE) or not, belong to events of special interest (AESI) or not. | 36Weeks |
| Blood Pressure change from baseline | Descriptive statistics summarizing changes in blood pressure (systolic and diastolic) will be compared between baseline levels and each predetermined time point. | 36 Weeks |
| Pulse change from baseline | Descriptive statistics summarizing changes in pulse will be compared between baseline levels and each predetermined time point. | 36 Weeks |
| Body temperature change from baseline | Descriptive statistics summarizing changes in body temperature will be compared between baseline levels and each predetermined time point. | 36 Weeks |
| Respiratory rate | Descriptive statistics summarizing changes in respiratory rate will be compared between baseline levels and each predetermined time point. | 36 Weeks |
| Complete or brief physical examination, at a minimum of General appearance, HEENT (head, eyes, ears, nose, throat), Neck, Lung/pulmonary, Chest, Neurological or not, Extremities,ect.to assess the physical health state. | Physical examination findings by body system will be summarized, presented with frequency counts and percentages. A complete or brief physical examination will be performed at Visit 1, Visit 2, End of Treatment Visit and Follow-up Visit. Height (cm) and weight (kg) will be measured and body mass index will be calculated and recorded at specified period. | 36 Weeks |
| Concomitant Medication | Concomitant medication usage will be summarized by the number and proportion of subjects and classified by the World Health Organization Drug Dictionary (WHO DD) based on Anatomical Therapeutic Chemical Classification System (ATC) code level 3. | 36 Weeks |
| Change in twelve-lead electrocardiogram parameters | Change in electrocardiogram parameters including heart rate (HR), QRS, RR, PR, and QT interval (QTcF and QTcB) relative to baseline will be summarized descriptively by visits and groups. The within-group changes from baseline to each visit will be summarized and will be compared with a paired t-test for continuous measurements. Subject number and percentage with other clinically significant electrocardiogram findings in each visit will be summarized by groups. A general assessment of the 12-lead electrocardiogram will be presented as normal, abnormal clinical significance, or abnormal no clinical significance. | 36 Weeks |
| Clinical laboratory tests of hematology | Descriptive statistics summarizing changes in results of clinical laboratory tests of hematology from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided. | 36 Weeks |
| Clinical laboratory tests of coagulation | Descriptive statistics summarizing changes in results of clinical laboratory tests of coagulation from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided. | 36 Weeks |
| Clinical laboratory tests of clinical chemistry | Descriptive statistics summarizing changes in results of clinical laboratory tests of clinical chemistry from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided. | 36 Weeks |
| Clinical laboratory tests of urinalysis | Descriptive statistics summarizing changes in results of clinical laboratory tests of urinalysis from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided. | 36 Weeks |
| Clinical laboratory tests of hormones | Descriptive statistics summarizing changes in results of clinical laboratory tests of hormones from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided. | 36 Weeks |
| D020763 |
| Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |